Calliditas Therapeutics advances kidney disease drug, meeting primary endpoint in study 15-Aug-2023 By Liza Laws Calliditas Therapeutics AB’s phase 3 study looking at a cure for a kidney disease called IgA nephropathy (IgAN) has met its primary endpoint and the full data has been published in The Lancet.